Mr. Charles MaLette reports

SURENANO SCIENCE LTD. ACQUIRES GLUCAPHARM INC., ADVANCING SECOND-GENERATION FDA PATHWAY GLP-1 DRUG DEVELOPMENT

Surenano Science Ltd. has completed the acquisition of GlucaPharm Inc., a next-generation glucagon-like peptide (GLP) pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition of GlucaPharm meaningfully strengthens Surenano's platform by accelerating its transition from an enabling-technology company into a near-term pharmaceutical value creator within one of the fastest-growing global drug markets. GlucaPharm's GEP44 developments directly align with Surenano's strategy of next-generation solutions that improve performance, tolerability and delivery, mirroring Surenano's core value proposition: to improve how advanced therapeutics are delivered and experienced by patients.

As previous announced, this transaction has been structured as a share exchange, where a total consideration paid by Surenano for this acquisition amounts to 8,100,999 common shares of the company issued to GlucaPharm shareholders and warrants to purchase five million common shares of the company issued to the holder of GlucaPharm warrants, per the terms of the agreement (refer to press release dated Nov. 19, 2025). The shares issued to GlucaPharm securityholders will be subject to the following hold period legend: The securities may not be sold, transferred, hypothecated or otherwise traded until the later of the approval by the Canadian Securities Exchange of a 2026 annual Form 5A submitted by Surenano and the release of the company's 2026 annual audited financial statements.

The company is also pleased to announce the appointment of Dr. Nihar R. Pandey as a director and chief scientific officer. Dr. Pandey is an experienced biochemist and clinical researcher with over 25 years of expertise in drug discovery and development. He has developed several intellectual-property-protected drug formulations and led advancements in R&D (research and development) and regulatory compliance. Dr. Pandey has a PhD in clinical biochemistry and has received postdoctoral training from the Department of Medicine, University of Montreal, Clinical Research Institute of Montreal and McGill University. He was appointed as a research scientist at the University of Ottawa Heart Institute and Hospitals (OHRI-Neuroscience) and was a group leader for drug discovery and development at Liponex Inc. in Ottawa, Canada.

GlucaPharm is developing GEP44, a novel, patented peptide developed by researchers at Syracuse University, which has demonstrated significant weight reduction and blood glucose normalization in preclinical studies, without the nausea and gastrointestinal side effects commonly associated with first-generation GLP-1 drugs currently on the market (such as Ozempic, Wegovy and Mounjaro). GEP44 is exclusively licensed from Syracuse University and represents a second-generation GLP opportunity targeting comparable or superior efficacy with improved patient tolerability.

The global GLP market remains in its early stages and is currently dominated by injectable, first-generation therapies such as Ozempic and Mounjaro, which have generated substantial revenues and strong market adoption. GlucaPharm's platform is focused on advancing a differentiated GLP asset with the potential for non-injectable administration, including oral, sublingual or nasal delivery, which management believes could materially expand patient adoption and long-term market penetration.

GlucaPharm is advancing GEP44 in collaboration with an experienced Australian contract research organization (CRO), with an IND-enabling (investigational new drug) FDA (U.S. Food and Drug Administration) study followed by phase I clinical trial expected to commence in Australia in the coming months. Key development milestones are anticipated over the next six to nine months, including IND progression and early clinical validation.

"This acquisition marks a transformational milestone for Surenano," said Charles MaLette, chief executive officer of Surenano. "GlucaPharm provides the company with a highly differentiated GLP asset at a time when demand for effective, better-tolerated metabolic therapies continues to accelerate globally. With an experienced development team, a clear FDA pathway and strong institutional support, we believe GEP44 positions Surenano to participate meaningfully in one of the most significant pharmaceutical markets of the decade."

Surenano recently completed $1.25-million in financing (refer to press release dated Dec. 10, 2025), including warrants exercisable at 35 cents, intended to support near-term development and subsequent financing rounds. The combined company is supported by a management team with demonstrated experience in drug discovery, obesity and diabetes related research, advancing assets through the FDA regulatory pathway and capital markets experience.

As GEP44 advances through IND, phase I and phase II to phase III development toward FDA approval, management expects Surenano to be positioned as one of the only microcap public companies developing GLP technology, with direct exposure to the multihundred-billion-dollar GLP-1 metabolic market, and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.

About GlucaPharm Inc.

GlucaPharm is a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery.

About Surenano Science Ltd.

Surenano is a Canadian life sciences company focused on acquiring, developing and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. The initial business of Surenano is the sale and distribution of the Surenano surfactant, which is a ready-to-mix food-grade compound that provides the base for high-performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity and taste. The company has an exclusive licence to distribute the Surenano surfactant within Canada, Oklahoma, United States, and Colorado, United States. Surenano is now developing into a pharmaceutical-focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.

We seek Safe Harbor.